Bulletin from the extraordinary general meeting in Idogen AB on February 17, 2020

REGULATORY

Today, on February 17, 2020, an extraordinary general meeting was held in Idogen AB. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority

Resolution on approval of the board of directors’ resolution on rights issue of shares

The extraordinary general meeting resolved to approve the board of directors’ resolution of January 28, 2020 on a rights issue of a maximum of 48,491,533 shares, whereby the company may receive a total issue amount of SEK 29 million before issue costs. Those who are registered as shareholders in the company on the record date February 26, 2020 will receive one (1) subscription right per existing share. One (1) subscription right entitles to subscription of one (1) new share in the company at a subscription price of SEK 0.60 per share. Upon full subscription of all shares issued in the rights issue, the company’s share capital will increase with a maximum of SEK 3,394,407.31. The subscription period in the rights issue runs from and including March 2, 2020 to and including March 16, 2020.

Lund on February 17, 2020

Idogen AB (publ)

For additional information, please contact:
Anders Karlsson, CEO, Idogen AB
Tel: +46 (0) 709 18 00 10
E-mail: anders.karlsson@idogen.com

This information was submitted for publication, through the agency of the contact person set out above, on February 17, 2020.

This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply.

 

Attached file

Idogen AB   |   Medicon Village   |   Scheelevägen 2   |   SE-223 81 Lund   |  Sweden   |  E-mail: info at idogen dot com

This project has received funding from the European Union’s Horizon 2020 research and innovation programme.